Transarterial chemoembolization in hepatocellular carcinoma treatment during the COVID-19 pandemic
Abstract
COVID-19 pandemic has a significant impact on the treatment of hepatocellular carcinoma as a cause of delays in diagnosing and treating patients due to the limitations in access to reference centers. The availability of human resources for the care of patients with hepatocellular carcinoma has decreased, as has the availability of hospital beds and operating rooms. On the other side morbidity and mortality related to treatment are increased in patients with cirrhosis and cancer due to their immunocompromised status and thus a higher chance of contracting a severe form of the COVID-19 disease.In order to handle such a challenging situation it became essential to revise the actual recommendations for hepatocellular carcinoma strategies during COVID-19 pandemic and adapt them to daily practice in accordance with the current legislation while respecting the principles of good clinical practice.
References
1. Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, et al. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Reports. 2021;3(1):100199.
2. Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP reports. 2020;2(3):100113.
3. Denys A, Guiu B, Chevallier P, Digklia A, de Kerviler E, De Baere T. Interventional oncology at the time of COVID-19 pandemic: problems and solutions. Diagnostic and interventional imaging. 2020;101(6):347-53.
4. Inchingolo R, Acquafredda F, Tedeschi M, Laera L, Surico G, Surgo A, et al. Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic. World Journal of Gastroenterology. 2021;27(25):3780.
5. Shiina S, Gani RA, Yokosuka O, Maruyama H, Nagamatsu H, Payawal DA, et al. APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. Hepatology International. 2020;14:920-9.
6. Akbulut S, Garzali IU, Hargura AS, Aloun A, Yilmaz S. Screening, surveillance, and management of hepatocellular carcinoma during the COVID-19 pandemic: a narrative review. Journal of Gastrointestinal Cancer. 2022:1-12.
7. Kudo M, Kurosaki M, Ikeda M, Aikata H, Hiraoka A, Torimura T, et al. Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC. Hepatology Research. 2020;50(9):1004-14.
8. Iavarone M, Sangiovanni A, Carrafiello G, Rossi G, Lampertico P. Management of hepatocellular carcinoma in the time of COVID-19. Annals of oncology. 2020;31(8):1084-5.
9. Chan SL, Kudo M. Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. Liver cancer. 2020;9(5):491-502.
10. Yu J, Ouyang W, Chua ML, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA oncology. 2020;6(7):1108-10.
11. Barry A, Apisarnthanarax S, O'Kane GM, Sapisochin G, Beecroft R, Salem R, et al. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. The Lancet Gastroenterology & Hepatology. 2020;5(8):765-75.
12. Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID‐19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72(1):287-304.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md). 2011;53(3):1020.
14. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver International. 2015;35(9):2155-66.
15. Chen L-C, Chiou W-Y, Lin H-Y, Lee M-S, Lo Y-C, Huang L-W, et al. Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial. BMC cancer. 2019;19(1):1-11.
16. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovascular and interventional radiology. 2007;30:6-25.
17. Kaseb AO, Tran Cao HS, Mohamed YI, Qayyum A, Vence LM, Blando JM, et al. Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. American Society of Clinical Oncology; 2020.
18. Liapi E, Geschwind J-FH. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovascular and interventional radiology. 2011;34:37-49.
19. Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Bioscience trends. 2017;11(4):389-98.
20. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. Journal of hepatology. 2007;46(3):474-81.
21. Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer research. 2012;32(5):1769-74.
22. Savic LJ, Chen E, Nezami N, Murali N, Hamm CA, Wang C, et al. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma—A Propensity Score Weighted Comparison of Efficacy and Safety. Cancers. 2022;14(23):5847.
23. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovascular and interventional radiology. 2010;33:41-52.
24. Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World journal of gastroenterology: WJG. 2015;21(36):10327.
25. Raoul J-L, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer treatment reviews. 2019;72:28-36.
26. O’Leary C, Mahler M, Soulen MC. Liver-directed therapy for hepatocellular carcinoma. Chin Clin Oncol. 2021;10(1):8.
27. Meyer T, Chan S, Park J. Management of HCC during COVID‐19: ILCA guidance. Association I-ILC, editor. 2020.
28. Chagas AL, da Fonseca LG, Coelho FF, da Cunha Saud LR, Abdala E, Andraus W, et al. Management of hepatocellular carcinoma during the COVID-19 pandemic-São Paulo Clínicas liver cancer group multidisciplinary consensus statement. Clinics. 2020;75.
29. Gaba R, Lokken R, Hickey R, Lipnik A, Lewandowski R, Salem R, et al. Society of interventional radiology standards of practice committee quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol. 2017;28:1210-23.
30. Jin Z-C, Chen L, Zhong B-Y, Zhu H-D, Zeng C-H, Li R, et al. Impact of COVID-19 pandemic on intervals and outcomes of repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Frontiers in Oncology. 2021;11:602700.
31. Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. Journal of hepatology. 2012;56(5):1112-20.
32. Al‐Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group. The oncologist. 2020;25(6):e936-e45.
33. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182-236.
34. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The lancet oncology. 2020;21(3):335-7.
35. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv. 2020:2020.02. 03.931766.
36. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver international. 2020;40(5):998-1004.
37. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine. 2020;8(4):420-2.
38. Maia Chagas A, Molloy JC, Prieto-Godino LL, Baden T. Leveraging open hardware to alleviate the burden of COVID-19 on global health systems. PLoS biology. 2020;18(4):e3000730.
39. Gaba RC. Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. American Journal of Roentgenology. 2012;198(3):692-9.